pr-bio

R&D

PIPELINE

  • Clostridium Botulinum Toxin type A

    2017 IND submission, 2018 NDA(Export only)(expected)

    2019 Clinical study Phase I, 2020 Clinical study Phase III

    2021 Registration in Korea

  • Indication study

    Expanding indications including dynamic equinus foot deformity, upper limb spasticity and blepharospasm etc.

  • Formulation study

    Developing new formulation to improve stability and compliance

  • Modified Botulinum Toxin study

    Developing advanced botulinum toxin

  • Health supplement for Inner-beauty

    Developing health supplement for inner-beauty using marine bio extract

    Government(Ministry of Oceans and Fisheries)-funded R&D project